Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956627 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04956627 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 15 participants.
The verdict
NCT04956627, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of itraconazole, phenytoin and gemfibrozil on the drug levels of BMS-986166 and its active metabolite BMT-121795. Participants will be randomly assigned to one of four groups and will remain in the study clinic for the duration of treatment.
Interventions
- DRUG Itraconazole
- DRUG BMS-986166
- DRUG Gemfibrozil
- DRUG Extended Phenytoin Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2022-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04956627
The ClinicalTrials.gov registry entry for NCT04956627 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Itraconazole is the first listed.
NCT04956627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04956627 about?
NCT04956627 is a clinical study titled "A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants". The purpose of this study is to evaluate the effect of itraconazole, phenytoin and gemfibrozil on the drug levels of BMS-986166 and its active metabolite BMT-121795. Participants will be randomly assigned to one of four groups and will remain in the study clinic for the duration of treatment.
What is the current status of trial NCT04956627?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-07-28. Estimated completion is 2022-04-27.
What interventions are being tested in trial NCT04956627?
The interventions under investigation include: Itraconazole (DRUG), BMS-986166 (DRUG), Gemfibrozil (DRUG), Extended Phenytoin Sodium (DRUG).
Who is sponsoring clinical trial NCT04956627?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.